Data in support of a functional analysis of splicing mutations in the IDS gene and the use of antisense oligonucleotides to exploit an alternative therapy for MPS II
Liliana Matos,
Vânia Gonçalves,
Eugénia Pinto,
Francisco Laranjeira,
Maria João Prata,
Peter Jordan,
Lourdes R. Desviat,
Belén Pérez,
Sandra Alves
Affiliations
Liliana Matos
Research and Development Unit, Department of Human Genetics, INSA, Porto, Portugal
Vânia Gonçalves
Research and Development Unit, Department of Human Genetics, INSA, Lisbon, Portugal
Eugénia Pinto
Biochemical Genetics Unit, Center for Medical Genetics Jacinto Magalhães, Porto Hospital Center, Porto, Portugal
Francisco Laranjeira
Biochemical Genetics Unit, Center for Medical Genetics Jacinto Magalhães, Porto Hospital Center, Porto, Portugal
Maria João Prata
Department of Biology, Faculty of Sciences, University of Porto, Porto, Portugal
Peter Jordan
Research and Development Unit, Department of Human Genetics, INSA, Lisbon, Portugal
Lourdes R. Desviat
Centro de Diagnóstico de Enfermedades Moleculares, Centro de Biología Molecular Severo Ochoa, UAM-CSIC, Universidad Autónoma de Madrid, Madrid, Spain
Belén Pérez
Centro de Diagnóstico de Enfermedades Moleculares, Centro de Biología Molecular Severo Ochoa, UAM-CSIC, Universidad Autónoma de Madrid, Madrid, Spain
Sandra Alves
Research and Development Unit, Department of Human Genetics, INSA, Porto, Portugal
This data article contains insights into the methodology used for the analysis of three exonic mutations altering the splicing of the IDS gene: c.241C>T, c.257C>T and c.1122C>T. We have performed splicing assays for the wild-type and mutant minigenes corresponding to these substitutions. In addition, bioinformatic predictions of splicing regulatory sequence elements as well as RNA interference and overexpression experiments were conducted. The interpretation of these data and further extensive experiments into the analysis of these three mutations and also into the methodology applied to correct one of them can be found in “Functional analysis of splicing mutations in the IDS gene and the use of antisense oligonucleotides to exploit an alternative therapy for MPS II” Matos et al. (2015) [1].